ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival

Zhang, Chan-Yuan; Sun, Hao; Su, Jun-Wei; Chen, Yu-Qing; Zhang, Shi-Ling; Zheng, Ming-Ying; Li, Yu-Fa; Huang, Jie; Zhang, Chao; Tai, Zai-Xian; Cai, Miao; Zhang, Xu-Chao; Su, Jian; Xu, Chong-Rui; Yan, Hong-Hong; Chen, Hua-Jun; Wu, Yi-Long*; Yang, Jin-Ji*广东省人民医院; 南方医科大学
Lung Cancer2023-1DOI: 10.1016/j.lungcan.2022.11.016
6被引8阅读
引用收藏
分享

摘要

Objectives: Transformed small-cell lung cancer (T-SCLC) has an extremely poor prognosis, and no remedies based on immunotherapy have been evaluated among T-SCLC patients. We retrospectively analysed the efficacy and safety of combining atezolizumab with chemotherapy for T-SCLC.Methods: Forty-seven patients harbouring EGFR mutations who developed T-SCLC were enrolled. Eleven patients who used immunotherapy were defined as the I/O group, and the remaining 36 were defined as the Non-I/O group. Clinical characteristics, pathological data, and survival outcomes were collected. RNA sequencing and whole-exome sequencing (WES) were performed for in-depth analysis.Results: All patients received at least one line of EGFR-TKI before rebiopsy to confirm T-SCLC. Nine patients received atezolizumab-bevacizumab-carboplatin-paclitaxel (albumin-bound) (ABCP), and the remaining 2 received atezolizumab-etoposide-carboplatin (ECT) in the I/O group. The objective response rate was 73 % (8/ 11). The median progression-free survival (mPFS) of T-SCLC on post-transformation therapy with I/O group and Non-I/O group was 5.1 m and 4.1 m, respectively. The median post-T-SCLC overall survival of the I/O group was significantly longer than that Non-I/O group (20.2 m vs 7.9 m, P < 0.01). T-SCLC harbouring EGFR L858R tended to be longer than EGFR 19del (mPFS: not reached vs 3.7 m, P = 0.11). Positive PD-L1 status was also associated with PFS benefits (mPFS: 6.0 m vs 3.7 m, P = 0.20). Furthermore, RNA sequencing revealed that expression of SFTPA1 is significantly higher in the durable clinical benefit group. WES showed that STC2 mu-tation is more frequently observed at the time-point immunotherapy acquired resistance. Combination therapy based on a PD-L1 inhibitor was well tolerated, and the safety profile was consistent with previously reported studies.Conclusion: Our study first demonstrated that a PD-L1 inhibitor combined with chemotherapy & PLUSMN; bevacizumab could be a potential safe option for specific SCLC-transformed patients. Subsequent studies with more patients are essential to verify the efficacy and potential biomarkers.

学科与关键词

关键词
EGFR-MutantNon-small cell lung cancerSmall-cell lung cancerTransformationImmune checkpoint inhibitors
相关
加载中…
  • Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
    Zhang, Shi-Ling; Zhang, Chan -Yuan; Chen, Yu-Qing; Li, Yu -Fa; Xie, Zhi; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Huang, Jie; Sun, Hao; Zheng, Ming-Ying; Xiao, Fa-Man; Yan, Hong-Hong; Lu, Dan-Xia; Lv, Zhi-Yi; Wu, Yi-Long; Chen, Hua-Jun*; Yang, Jin-Ji*Journal of Thoracic Disease, 2023, 15(9).
  • Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
    Zhang, C.; Zhang, S.; Yao, Y.; Gao, Y.; Huang, J.; Peng, K.; Gao, Q.; Chen, H.; Xu, C.; Zhang, X.; Wu, Y.; Yang, J.被引 3
  • Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report
    Xue, Lei; Chen, Baishen; Lin, Junshuang; Peng, Jiangzhou*Annals of Palliative Medicine, 2021, 10(1): 828-835.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2023-01
卷期
第 175 卷
页码
68-78
DOI
10.1016/j.lungcan.2022.11.016
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82102966]; Natural Science Founda-tion of Guangdong Province [2019A1515010931]; High-level Hospital Construction Project [DFJH201809]; Key Lab System Project of Guangdong Science and Technology Department - Guangdong Provincial Key Lab-oratory of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • Z

    Zhang, Chan-Yuan (第一作者)

    2 · southern med univ · guangdong prov peoples hosp

  • S

    Sun, Hao

    guangdong prov peoples hosp

查看全部 18 位作者收起作者
  • S

    Su, Jun-Wei

    guangdong prov peoples hosp

  • C

    Chen, Yu-Qing

    guangdong prov peoples hosp

  • Z

    Zhang, Shi-Ling

    guangdong prov peoples hosp

  • Z

    Zheng, Ming-Ying

    guangdong prov peoples hosp

  • L

    Li, Yu-Fa

    guangdong prov peoples hosp

  • H

    Huang, Jie

    guangdong prov peoples hosp

  • Z

    Zhang, Chao

  • T

    Tai, Zai-Xian

  • C

    Cai, Miao

    guangdong prov peoples hosp

  • Z

    Zhang, Xu-Chao

  • S

    Su, Jian

    guangdong prov peoples hosp

  • X

    Xu, Chong-Rui

    guangdong prov peoples hosp

  • Y

    Yan, Hong-Hong

    guangdong prov peoples hosp

  • C

    Chen, Hua-Jun

    guangdong prov peoples hosp

  • W

    Wu, Yi-Long (通讯)

    2 · southern med univ · guangdong prov peoples hosp

  • Y

    Yang, Jin-Ji (通讯)

    guangdong prov peoples hosp · 2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417